We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Anti-HEV Assays Evaluated for Diagnosing Acute Hepatitis E Infections

By LabMedica International staff writers
Posted on 04 Dec 2013
The performance of two anti-HEV IgG and IgM assays were assessed for diagnosing acute HEV infections in immunocompromised patients.

Hepatitis E virus is an emerging concern in immunocompromised patients, who may become chronically infected. More...
No data were available for immunocompromised patients, who might not mount a good antibody response to HEV and might thus test negative for anti-HEV antibodies. The two anti-HEV assays evaluated in the study, published in the Journal of Clinical Virology online ahead of print October 15, 2013, were those from Adaltis and Wantai, the two main serological assays employed in Europe, specifically: EIAgen HEV IgG and IgM kits (Adaltis; Eurobio, France), based on synthetic antigens encoded by the ORF2 and ORF3 genes of HEV1 and HEV2; and the HEVIgM and IgG ELISA 3.0 Wantai kits (Wantai Biological Pharmacy Enterprise Co.; China), based on a recombinant HEV1 antigen, pE2. Tests were performed as recommended by the manufacturers.

Specificities were estimated by testing samples from 2 to 3 year-old children and blood donors and sensitivities were estimated by testing 40 immunocompromised patients acutely infected. Both anti-HEV IgM assays were highly specific (99.6% and 100%). The sensitivity of the Adaltis was 87.5%, and that of Wantai was 85%. The specificities of anti-HEV IgG Wantai (97.8%) and Adaltis tests (89.5%, = 0.1) were similar but the Wantai test was more sensitive (45%) than the Adaltis test (15%, < 0.001). None of the samples was anti-HEV IgM negative and IgG positive.

The authors, led by Dr. Florence Abravanel of the Centre Hospitalier Universitaire de Toulouse (University Hospital Center of Toulouse; Toulouse, France), concluded that these anti-HEV IgM assays performed well in immunosuppressed patients with acute hepatitis E and can be used as first line virological tools. Testing for anti-HEV IgG and IgM simultaneously at the acute phase did not improve the diagnostic performance. In contrast, molecular detection of HEV RNA appears essential to exclude an HEV infection in patients who are negative for anti-HEV IgM and to assess the evolution of hepatitis E three months thereafter.

Related Links:

Centre Hospitalier Universitaire de Toulouse



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.